Effect of dutasteride on reduction of intraoperative bleeding related to transurethral resection of the prostate;Effet du dutastéride sur la réduction des saignements per-opératoires liés à la résection transuréthrale de prostate

Progres en Urologie

Volumn 15, Issue 6, 2005, Pages 1085-1089

  Boccon Gibod, Laurent ^a   Valton, Michel ^b   Ibrahim, Hussein ^c   Boccon Gibod, Liliane ^d   Comenducci, Andrea ^e  

^a BICHAT HOSPITAL   (France)

^b Service d'Urologie   (France)

^c CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^d ARMAND TROUSSEAU HOSPITAL   (France)

^e GLAXOSMITHKLINE   (France)

Author keywords

5 alpha reductase inhibitor; Benign prostatic hyperplasia; Dutasteride; Peroperative bleeding; Transurethral resection of the prostate

Indexed keywords

AZASTEROID; DUTASTERIDE;

AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSURETHRAL RESECTION;

AGED; AGED, 80 AND OVER; AZASTEROIDS; BLOOD LOSS, SURGICAL; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 33646184148     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. ANDRIOLE G.L., HUMPHREY P., RAY P., GLEAVE M.E., TRACHTENBERG J., THOMAS L.N., LAZIER C.B., RITTMASTER R.S.: Effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J. Urol., 2004; 172: 915-919.
2. BETTENCOURT M.C., BAUER J.J., SESTERHEM I.A., CONNELLY R.R., MOUL J.: CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J. Urol., 1998; 160: 459-465.
3. CETINKAYA M., GUNCE S., ULUSOY E., AKSOY F., YILDIZ O., ADSAN O., OZDEN C.: Relationship between prostate specific antigen density, microvessel density and prostatic volume in benign prostatic hyperplasia and advanced prostatic carcinoma. Int. Urol. Nephrol., 1998; 30: 581-585.
4. CREA G., SANFILIPPO G., ANASTASI G., MAGNO C., VIZZINI C., INFERRERA A.: Pre-surgical finasteride therapy in patients treated endoscopically for benign prostatic hyperplasia. Urol. Int., 2005; 74: 51-53.
5. DONOHUE J.F., HARBINDER S., ABRAHAM R., NATALWALA S., THOMAS D.R., FOSTER M.C.: Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of the role of finasteride for decreasing operative blood loss. J Urol 2002; 168: 2024-6.
6. FOLEY S.J.: Benign prostatic hyperplasia-related haematuria and the effect of finasteride. The Prostate Journal, 2000; 2: 189-92.
7. FOURCADE R.O., VALLANCIEN G. et les membres du Club d'Urologie Pratique: Morbidité de la résection endoscopique de la prostate: étude prospective à 3 mois. Progrès en Urologie 2000; 10: 48-52.
8. GETTMAN M.T., BERGSTRALH E.J., BLUTE M., ZINCKE H., BOSTWICK, D.G.: Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis. Urology 1998; 51: 79-85.
9. HAGERTY J.A., GINSBERG P.C., HARMON J.D., HARKAWAY R.C.: Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology 2000; 55: 684-9.
10. HAGGSTROM S., TORRING N., MOLLER K., JENSEN E., LUND L., NIELSEN J.E., BERGH A., DAMBERS J.E.: Effects of finasteride on vascular endothelial growth factor. Scan J Urol Nephrol 2002; 36: 182-7.
11. LUND L., MOLLER ERNST-JENSEN K., TORRING N., NIELSEN J.E.: Impact of finasteride treatment on perioperative bleeding before transurethral resection: A prospective randomized study. Scan J Urol Nephrol 2005; 39: 160-2.
12. MARSHALL S., NARAYAN P.: Treatment of prostatic bleeding: suppression of angiogenesis by androgen deprivation. J Urol 1993; 149: 1553-4.
13. ÖZDAL L., ÖZDEN C., BENLI K., GÖKKAYA S., BULUT S., MEMIS A. Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized controlled study. Prostate Cancer and Prostatic Diseases, 2005, 8, 215-8.
14. PAREEK G., SHEVCHUK M., ARMENAKAS N.A., VASJOVIC L., HOCHBERG D.A., BASILLOTE J.B., FRACCHIA J.A.: The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 2003; 169: 20-3.
15. ROEHRBORN G.G., BOYLE P., NICKEL J.C., HOEFNER K., ANDRIOLE G., ON BEHALF OF THE ARIA3001, ARIA3002, AND ARIA3003 STUDY INVESTIGATORS.: Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41.
16. SANDFELDT L., BAILEY D.M., HAHN R.G.: Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride. Urology, 2001; 58: 972-976.
17. SHIH S-J., DALL'ERA M.A., WESTPHAL J.R., YANG J., SWEEP C.G.J., CANDOUR-EDWARDS R., EVANS C.P.: Elements regulating angiogenesis and correlative microvessel density in benign hyperplastic and malignant prostate tissue. Prostate Cancer Prostatic Dis., 2003; 6: 131-137